SURVYR

IMVT

Immunovant, Inc.
$29.42
+$0.54 (1.87%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-10%+20%+51%+81%+112%Oct 2025Oct 2026Apr 202652w high $45.4252w low $19.21
IMVTSPY
Wall St. Highest PT $66.00 (+124.3%) Wall St. Avg PT $48.88 (+66.1%)
$21$33$45$56$68POC $26Hi $66Avg $49
Underwater Drawdown %Max DD -40.5%Current -34.6%
0.0%-40.5%
Relative Strength vs SPY+23.4% vs SPYOutperforming
+111%0%-111%
1W
+$1.04 (3.66%)
1M
−$4.07 (12.15%)
3M
−$9.19 (23.80%)
6M
+$2.47 (9.17%)
YTD
+$4.00 (15.74%)
1Y
+$7.44 (33.85%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
16 analysts · mean score 1.59
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$29.42
Average target$48.88
+$19.45 (+66.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$30.00
Median$48.88
High$66.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$5.9B
P/E (next 12 months, estimated)-10.3
52-week range$19.21 – $45.42
Dividend yieldNo dividend
Analyst consensusBuy (16)
Average analyst price target$48.88 (+66%)

What they do

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for IMVT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

IMVT earningsNext report in 11 days
Next report · quarter Sep 2026
Mon Nov 9, 2026Before the open
EPS consensus-$0.72
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.68est -$0.61−10.5%Below estimates
May 20, 2026-$0.67est -$0.63−7.5%Below estimates
Feb 6, 2026-$0.54est -$0.69+22.4%Above estimates
Nov 10, 2025-$0.65est -$0.73+10.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:23:10 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.760.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.
Insider trades
Stout Jay S
Chief Technology Officer · 2026-10-21
Sell
$75.1K
Gloria Melanie
Chief Operating Officer · 2026-10-07
Sell
$71.8K
Van Tuyl Christopher
Chief Legal Officer · 2026-10-07
Sell
$42.5K
Stout Jay S
Chief Technology Officer · 2026-10-07
Sell
$51.2K
Stout Jay S
Chief Technology Officer · 2026-10-07
Sell
$70.9K
Venker Eric
Director, Chief Executive Officer · 2026-10-02
Sell
$119.6K
Van Tuyl Christopher
Chief Legal Officer · 2026-09-23
Sell
$103.5K
Pande Atul
Director · 2026-08-28
Sell
$64.9K
Gloria Melanie
Chief Operating Officer · 2026-08-20
Sell
$135.0K
Pande Atul
Director · 2026-07-24
Sell
$59.7K
Stout Jay S
Chief Technology Officer · 2026-07-23
Sell
$110.5K
Girao Tiago
Chief Financial Officer · 2026-07-23
Sell
$263.0K

Stats refreshed 2026-10-27 18:23:10 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026